RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca

Backed By Funds From HealthCare Royalty Partners

 
• By John Davis
  
Stomach
GI diseases are a focus for RedHill Biopharma • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business